MMRF CoMMpass Study
What is the MMRF CoMMpass℠ study?
The MMRF CoMMpass℠ study is a groundbreaking, landmark study designed to uncover the molecular segments and variations in multiple myeloma. The most ambitious study of its kind in multiple myeloma, the CoMMpass study is the cornerstone of the larger MMRF Personalized Medicine Initiative. The CoMMpass study will collect and analyze tissue samples and genetic information from approximately 1,000 multiple myeloma patients over the next 5 years. This research may have near-term as well as far-reaching impact on the disease.
The goals of the study include:
- Targeting of existing therapies. Patients with different genetic markers are known to react more positively to some therapies than others. The goal of the CoMMpass study is to create a guide to which treatments work best for specific patients, allowing doctors to select the most effective treatment for each patient.
- Personalized treatments. Genetically targeted treatments may offer the best hope for treating and curing multiple myeloma. The CoMMpass study will give researchers access to data and insights that will help them design the next generation of multiple myeloma treatments targeted towards patients with specific genetic markers.
What is Personalized Medicine?
Personalized medicine is an approach to disease diagnoses, treatment and prevention that links disease treatment with an individual's myeloma disease features. The Personalized Medicine Initiative will take the insights gained from the CoMMpass study to help speed the development of effective treatments tailored for each patient's disease.
How do I find out more?
Those who are interested in learning more about the MMRF CoMMpass study and whether they qualify, should contact the MMRF Patient Support Center at 1.866.603.6628 or firstname.lastname@example.org.